Earnings call transcript: Merck Q2 2025 results beat EPS forecast, stock dips

Merck & Co. reported Q2 2025 EPS of $2.13, surpassing the $2.03 forecast by 4.93%, but its stock declined 2.75% pre-market, primarily due to a slight revenue miss at $15.81 billion against expectations of $15.87 billion. The company experienced a 1.8% year-over-year net sales decrease, impacted by currency headwinds, though organic sales grew 2%. Despite challenges in its Electronics division, Merck narrowed its full-year organic sales growth guidance to 2-5% and raised its EBITDA pre-organic growth guidance to 4-8%, signaling confidence in continued profitable expansion through strategic portfolio management and pipeline advancements.

Analysis

Merck & Co. presented a mixed financial picture for Q2 2025, characterized by a notable earnings beat but a slight revenue shortfall that prompted a negative pre-market stock reaction. The company reported an EPS of $2.13, surpassing the $2.03 forecast by 4.93%, yet revenue of $15.81 billion missed the consensus estimate of $15.87 billion. The results reveal a significant divergence in segmental performance. The Life Science and Healthcare divisions demonstrated robust underlying strength, each delivering 4% organic sales growth, driven by an 11% expansion in Process Solutions and strong performance from key drugs like Mavenclad. In contrast, the Electronics division faced substantial headwinds, with organic sales contracting 6% due to a more than 30% decline in its DS&S business from customer project delays. This segment's profitability was further eroded by two non-recurring items. Despite these challenges and a significant currency headwind that reduced reported sales by 4.2%, management signaled confidence by narrowing its full-year organic sales growth guidance to 2-5% and, more importantly, raising its EBITDA pre-organic growth forecast to 4-8%, reflecting effective cost management, strategic portfolio adjustments like the SpringWorks acquisition, and underlying profitability in its core growth engines.

Key Decisions for Investors

• Investors should scrutinize the bifurcated performance, as the anemic results in the Electronics division, driven by delayed customer projects, are currently masking the robust organic growth and strong execution within the Life Science and Healthcare segments.
• The successful integration of the recently acquired SpringWorks Therapeutics and the sales trajectory of its drug OXIVIO are critical catalysts to monitor, representing a key pillar of the company's strategy to accelerate growth ahead of future patent cliffs.
• Despite the stock's defensive characteristics, including a low beta of 0.39 and a 55-year dividend history, the negative reaction to a minor revenue miss highlights market sensitivity to cyclical weakness and currency headwinds, warranting a close watch on the company's ability to meet its upgraded profitability targets.